Jade Biosciences Announces Pricing of Public Offering of Common Stock
Jade Biosciences, a clinical-stage biotech company focused on autoimmune therapies, announced the pricing of a $150 million public offering of 10 million shares to advance its clinical and preclinical programs. The proceeds will fund clinical trials, manufacturing, R&D, capital spends, and general corporate purposes. The offering is expected to clo…